Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 15/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 8/20 | 0.47 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.46 |
| ▸ | WEE1 | P30291 | 1/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.46 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.44 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4462803 | 0.82 | ROCK2 (0.46) | ROCK2ROCK1MAPKAPK2WEE1ALK | |
| SCHEMBL4383142 | 0.72 | MAT2A (0.45) | ROCK2ROCK1ALK | |
| SCHEMBL16638038 | 0.70 | ROCK2 (0.61) | ROCK2ROCK1MAPKAPK2TNIK | |
| SCHEMBL26715276 | 0.69 | MAPKAPK2 (0.71) | ROCK2ROCK1MAPKAPK2 | |
| SCHEMBL12680064 | 0.67 | MAPKAPK2 (0.52) | ROCK2ROCK1MAPKAPK2ALK | |
| SCHEMBL15639981 | 0.67 | KDR (0.55) | ROCK2ROCK1MAPKAPK2TNIKEIF2AK2 | |
| SCHEMBL22749728 | 0.67 | KDR (0.65) | ROCK2ROCK1MAPKAPK2TNIK | |
| SCHEMBL20774620 | 0.67 | ROCK2 (0.79) | ROCK2ROCK1 | |
| SCHEMBL30611501 | 0.67 | ROCK2 (0.79) | ROCK2ROCK1 | |
| SCHEMBL30611438 | 0.66 | MKNK1 (0.58) | ROCK2ROCK1MAPKAPK2TNIK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795271-B2 | Substituted pyrimidinones | PHARMACIA CORPORATION (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090306108-A1 | SUBSTITUTED PYRIMIDINONES | PFIZER INC | 2009-12-10 | — | — | US | disclosed |
| US-20070167621-A1 | SUBSTITUTED PYRIMIDINONES | PHARMACIA CORPORATION (US) | 2007-07-19 | — | — | US | disclosed |
| US-7183287-B2 | Substituted pyrimidinones | PHARMACIA CORPORATION (US) | 2007-02-27 | — | — | US | disclosed |
| US-20040242608-A1 | Substituted pyrimidinones | PHARMACIA LLC | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306108-A1 | SUBSTITUTED PYRIMIDINONES | MAPK1, MAP3K8, MAP3K7 | ROCK2 443/4885ROCK1 243/4885MAPKAPK2 30/4885 |
| US-20040242608-A1 | Substituted pyrimidinones | MAPK1, MAPK7, MAP3K8 | ROCK2 409/4885ROCK1 192/4885MAPKAPK2 22/4885 |
| US-20070167621-A1 | SUBSTITUTED PYRIMIDINONES | MAPK1, MAP3K8, MAP3K7 | ROCK2 443/4885ROCK1 243/4885MAPKAPK2 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.